Member Info for Fourprinces

Hanno podcast today

Partners

You thought wrong

Yup

https://www.dccae.gov.ie/en-ie/natural-resources/consultations/Pages/Application-for-consent-for-a-site-survey-at-Barryroe,-North-Celtic-Sea,-South-West-Coast-Ireland-proposed-by-Exola-DAC-wh.aspx

Permit news last night
https://www.dccae.gov.ie/en-ie/natural-resources/consultations/Pages/Application-for-consent-for-a-site-survey-at-Barryroe,-North-Celtic-Sea,-South-West-Coast,-Ireland-proposed-by-Exola-DAC-wh.aspx

13. 25 if people get their head around the tax value.

Very naked https://twitter.com/riddler_smitb/status/1153219605487374336?s=21

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/d37a236e-a940-11e9-984c-fac8325aaa04

Silence Therapeutics nearly doubled after the gene science developer licensed its flagship technology to Mallinckrodt Pharmaceuticals.

The US-based, Ireland-domiciled drugmaker paid a $20m upfront payment as well as agreeing up to $666m in milestone payments and around $10m in research funding in exchange for exclusive rights to Silence’s SLN 500, an early-stage experimental drug that aims to regulate immune responses. Mallinckrodt also took options to sign similarly structured deals over two drugs in Silence development pipeline.

CLINICAL TRIALS UPDATE
Since the acquisition of IVIX in Q3 2018 the Group was continuing to run its Phase 3 clinical study of
BP101 in Russia. In Q1 2019 the pre-specified interim analysis was performed, and statistically significant
superiority of BP101 compared with placebo in terms of the study primary endpoint – change from
baseline in the mean number of satisfying sexual events (SSEs) after the first month of treatment, was
shown. The independent Data Monitoring Committee (DMC) has reviewed the interim analysis results
and has recommended to IVIX to early complete the trial due to early efficacy demonstration.
In line with DMC recommendation, IVIX has decided to early stop the patients’ recruitment to the
BP101-SD02-RUS Phase 3 study and to start preparations for early study completion. Corresponding
interim clinical trial report was sent to Russian Ministry of Health (Regulatory Authority).

They’re looking for a similar sum imho - that’s a 1500 bagger

As they point out themselves on the website

Only one pharmaceutical treatment, Addyi (flibanserin, antidepressant with selective action at serotonin 5-HT receptors), is marketed in the US for HSDD. Flibanserin efficacy in large US-based clinical studies was statistically significant over placebo, but demonstrated concomitant safety problems, such as risk of severe hypotension and syncope when taken together with alcohol or even Addyi alone, or Central Nervous System (CNS) depression (e.g., somnolence, sedation) with Addyi alone. Other common side effects included dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. In October 2015, Valeant Pharmaceticals acquired Sprout Pharmaceuticals, the producer of Addyi, for an aggregate purchase price of $1.45 billion, which included cash plus contingent consideration. Subsequently, in December 2017, Valeant completed the sale of Sprout to a buyer affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of Addyi beginning June 2019. Valeant noted that the sale of Sprout provided it with the opportunity to divest a business that was not core to its objectives, while also allowing it to resolve an ongoing legal matter between it and former shareholders of Sprout relating to compliance with certain contractual terms of the 2015 acquisition agreement with respect to the use of certain diligent efforts by Valeant to develop and commercialize Addyi.

There’s also the matter of the £14m+ worth of POLY shares they hold. Once they get this into one market, which I understand is imminent (they’ve already appointed the CMOs and packaging manufacturer) they’ll get bought out.

As well as the fact it's currently woefully undervalued compared to same stage peers there's the small matter of the company's holding in #POLY which, this morning, is currently worth £14m. Then there's their £1.3m holding in US stocks. Current midcap? £9m...

https://ovocabio.com/projects/ paragraphs 12-14

tbf he also looked at peer valuation at the same stage - the current MC is insanely low

I think you'll be surprised Pablo (M here)

Therefore data going through so it looks like all on track

And got this reply

It's an automatic process when shares come and go from the website so we must've been sent data that's brought it back into view again on the website. CH.

Asked LSE this: “Hiya. Just wanted to check something. infinity seems to have reappeared on your site despite being suspended for some time. I know it’s due back soon but just wondered as to why you’d put it back up https://www.lse.co.uk/SharePrice.asp?shareprice=INFT&share=Infinity-Eng